JP2017506675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506675A5 JP2017506675A5 JP2016572363A JP2016572363A JP2017506675A5 JP 2017506675 A5 JP2017506675 A5 JP 2017506675A5 JP 2016572363 A JP2016572363 A JP 2016572363A JP 2016572363 A JP2016572363 A JP 2016572363A JP 2017506675 A5 JP2017506675 A5 JP 2017506675A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 208000035475 disorder Diseases 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 239000001301 oxygen Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 229910052717 sulfur Chemical group 0.000 claims description 22
- 239000011593 sulfur Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 230000002062 proliferating effect Effects 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 7
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000017701 Endocrine disease Diseases 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 208000030172 endocrine system disease Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 2
- -1 pyrazol-4-yl Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946358P | 2014-02-28 | 2014-02-28 | |
| US61/946,358 | 2014-02-28 | ||
| US201461971376P | 2014-03-27 | 2014-03-27 | |
| US61/971,376 | 2014-03-27 | ||
| US201462096231P | 2014-12-23 | 2014-12-23 | |
| US62/096,231 | 2014-12-23 | ||
| PCT/US2015/018071 WO2015131080A1 (en) | 2014-02-28 | 2015-02-27 | Tyk2 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018227179A Division JP2019048885A (ja) | 2014-02-28 | 2018-12-04 | Ｔｙｋ２阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506675A JP2017506675A (ja) | 2017-03-09 |
| JP2017506675A5 true JP2017506675A5 (enExample) | 2018-03-15 |
| JP6526065B2 JP6526065B2 (ja) | 2019-06-05 |
Family
ID=54009662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572363A Active JP6526065B2 (ja) | 2014-02-28 | 2015-02-27 | Ｔｙｋ２阻害剤およびその使用 |
| JP2018227179A Withdrawn JP2019048885A (ja) | 2014-02-28 | 2018-12-04 | Ｔｙｋ２阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018227179A Withdrawn JP2019048885A (ja) | 2014-02-28 | 2018-12-04 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9340540B2 (enExample) |
| EP (2) | EP4019518A1 (enExample) |
| JP (2) | JP6526065B2 (enExample) |
| CN (1) | CN106661039B (enExample) |
| AU (1) | AU2015222865B2 (enExample) |
| CA (1) | CA2940666C (enExample) |
| ES (1) | ES2921874T3 (enExample) |
| TW (2) | TWI701245B (enExample) |
| WO (1) | WO2015131080A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI707852B (zh) | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| WO2018071794A1 (en) * | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| EP4338802A3 (en) * | 2017-03-08 | 2024-09-04 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| WO2018204830A2 (en) * | 2017-05-05 | 2018-11-08 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| ES2994013T3 (en) | 2017-07-28 | 2025-01-15 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| CA3069990A1 (en) * | 2017-08-01 | 2019-02-07 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors |
| CN114478544B (zh) | 2017-09-28 | 2023-06-16 | 上海海雁医药科技有限公司 | 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| JP2020537678A (ja) * | 2017-10-19 | 2020-12-24 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用 |
| CN111386272B (zh) | 2017-10-27 | 2023-01-06 | 费森尤斯卡比肿瘤学有限公司 | 一种改进的瑞博西尼及其盐的制备方法 |
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| US12486320B1 (en) * | 2018-01-15 | 2025-12-02 | Washington University | Compositions and methods for treatment of central nervous system (CNS) autoimmune associated diseases or disorders |
| UY38144A (es) | 2018-03-12 | 2019-10-31 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa |
| CA3093706A1 (en) | 2018-03-21 | 2019-09-26 | Xibin Liao | Jak inhibitors |
| CN108409638A (zh) * | 2018-05-18 | 2018-08-17 | 东南大学 | 一种Niraparib中间体（S）-3-（4-溴苯基）哌啶的制备方法 |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| US11174264B2 (en) | 2019-01-23 | 2021-11-16 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| US20220025510A1 (en) | 2019-03-15 | 2022-01-27 | Mitsubishi Materials Corporation | Tungsten oxide sputtering target |
| AU2020242723B2 (en) * | 2019-03-18 | 2021-12-16 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | BTK inhibitor, pharmaceutically acceptable salt, polymorph and application thereof |
| WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3150108A1 (en) | 2019-09-13 | 2021-03-18 | Neelu Kaila | Hpk1 antagonists and uses thereof |
| CN114901640A (zh) * | 2019-12-24 | 2022-08-12 | 兹杜斯生命科学有限公司 | 适用于治疗血脂异常的新型化合物 |
| WO2021180952A1 (en) * | 2020-03-13 | 2021-09-16 | Astrazeneca Ab | Fused pyrimidine compounds as kcc2 |
| CN111269134B (zh) * | 2020-04-01 | 2022-09-20 | 九江中星医药化工有限公司 | 一种苯甘氨酸及其衍生物的制备方法 |
| WO2022053931A1 (en) * | 2020-09-08 | 2022-03-17 | Galderma Holding SA | Novel jak inhibitor compounds, method for synthesizing same and use thereof |
| US12331046B2 (en) | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
| CN114644566A (zh) * | 2020-12-21 | 2022-06-21 | 抚顺顺能化工有限公司 | 一种2-氨基-2-苯基丁酸的制备方法 |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022179578A1 (zh) * | 2021-02-24 | 2022-09-01 | 南京明德新药研发有限公司 | 含有亚磺酰基吡啶结构的化合物以及应用 |
| CN117295737A (zh) | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| KR20240007155A (ko) | 2021-04-09 | 2024-01-16 | 님버스 클리오, 인코포레이티드 | Cbl-b 조절제 및 이의 용도 |
| WO2022233286A1 (zh) * | 2021-05-04 | 2022-11-10 | 上海喆邺生物科技有限公司 | 一类含氮杂环吡啶类化合物 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| JP2025527248A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用 |
| IL318577A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES |
| TW202416950A (zh) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | 雜芳基甲醯胺及相關gpr84拮抗劑及其用途 |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| US20250281498A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies |
| WO2025188955A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AU2002253619B2 (en) | 2001-04-27 | 2007-05-17 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same active ingredients |
| WO2003009852A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166718A0 (en) | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
| EP1611119A1 (en) | 2003-04-03 | 2006-01-04 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| US7425553B2 (en) | 2003-05-30 | 2008-09-16 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| ZA200604580B (en) * | 2003-11-19 | 2009-08-26 | Array Biopharma Inc | Heterocyclic inhibitors of Mek and methods of use thereof |
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| DK1856135T3 (da) | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser |
| KR20080011199A (ko) * | 2005-04-19 | 2008-01-31 | 교와 핫꼬 고교 가부시끼가이샤 | 질소 함유 복소환 화합물 |
| TWI337182B (en) | 2005-05-12 | 2011-02-11 | Abbott Lab | Apoptosis promoters |
| CN102321030A (zh) * | 2005-05-18 | 2012-01-18 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| JP5270353B2 (ja) | 2005-10-07 | 2013-08-21 | エクセリクシス， インク． | ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法 |
| MX391408B (es) | 2005-11-01 | 2025-03-21 | Impact Biomedicines Inc | Inhibidores de biaril meta-pirimidina de cinasas. |
| SI1966202T1 (sl) | 2005-12-13 | 2012-01-31 | Incyte Corp | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| HUE028086T2 (en) | 2006-09-22 | 2016-11-28 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US8486941B2 (en) | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2009054941A1 (en) * | 2007-10-25 | 2009-04-30 | Merck & Co., Inc. | Therapeutic compounds |
| ES2564422T3 (es) * | 2007-11-15 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Compuestos heterocíclicos que contienen N |
| AU2009223640B2 (en) | 2008-03-11 | 2013-07-04 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| RS54180B1 (sr) * | 2009-12-23 | 2015-12-31 | Takeda Pharmaceutical Company Limited | Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| EP2723746A1 (en) * | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
-
2015
- 2015-02-27 WO PCT/US2015/018071 patent/WO2015131080A1/en not_active Ceased
- 2015-02-27 EP EP22153229.4A patent/EP4019518A1/en active Pending
- 2015-02-27 US US14/634,041 patent/US9340540B2/en active Active
- 2015-02-27 ES ES15755242T patent/ES2921874T3/es active Active
- 2015-02-27 CN CN201580021113.2A patent/CN106661039B/zh active Active
- 2015-02-27 CA CA2940666A patent/CA2940666C/en active Active
- 2015-02-27 EP EP15755242.3A patent/EP3110820B1/en active Active
- 2015-02-27 AU AU2015222865A patent/AU2015222865B2/en active Active
- 2015-02-27 JP JP2016572363A patent/JP6526065B2/ja active Active
- 2015-03-02 TW TW104106745A patent/TWI701245B/zh active
- 2015-03-02 TW TW108106527A patent/TWI754794B/zh active
-
2016
- 2016-04-13 US US15/097,402 patent/US9630970B2/en active Active
-
2017
- 2017-03-13 US US15/457,657 patent/US10196390B2/en active Active
-
2018
- 2018-12-04 JP JP2018227179A patent/JP2019048885A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506675A5 (enExample) | ||
| IL271999B2 (en) | Tyk2 inhibitors and uses thereof | |
| JP2018532706A5 (enExample) | ||
| JP2018529739A5 (enExample) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2016505012A5 (enExample) | ||
| JP2013542256A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2019527718A5 (enExample) | ||
| JP2016539996A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| JP2013515786A5 (enExample) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| JP2017509689A5 (enExample) | ||
| JP2019527230A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2019530699A5 (enExample) | ||
| JP2010526098A5 (enExample) | ||
| JP2016513663A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2011500685A5 (enExample) | ||
| JP2017536416A5 (enExample) |